Oncología médica
Especialidad
Universidad Complutense de Madrid
Madrid, EspañaPublikationen in Zusammenarbeit mit Forschern von Universidad Complutense de Madrid (25)
2024
-
Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer
Clinical Cancer Research, Vol. 30, Núm. 14, pp. 3036-3049
2023
-
Identification of fatty acid amide hydrolase as a metastasis suppressor in breast cancer
Nature Communications, Vol. 14, Núm. 1
-
Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme
European Journal of Cancer, Vol. 182, pp. 3-14
2022
-
Considerations on diagnosis and surveillance measures of PTEN hamartoma tumor syndrome: clinical and genetic study in a series of Spanish patients
Orphanet Journal of Rare Diseases, Vol. 17, Núm. 1
-
Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment
Journal of Clinical Investigation, Vol. 132, Núm. 7
2021
-
LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology
Cancer Medicine, Vol. 10, Núm. 17, pp. 5878-5888
-
Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL
Annals of Oncology, Vol. 32, Núm. 4, pp. 488-499
-
The pseudokinase TRIB3 negatively regulates the HER2 receptor pathway and is a biomarker of good prognosis in luminal breast cancer
Cancers, Vol. 13, Núm. 21
2019
-
A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer
Frontiers in Oncology, Vol. 9, Núm. APR
-
A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012–12 (EDALINE) study
Investigational New Drugs, Vol. 37, Núm. 1, pp. 98-108
-
Cohort profile: Design and methods of the PREDIMED-Plus randomized trial
International Journal of Epidemiology, Vol. 48, Núm. 2, pp. 387-388o
-
Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2−) early breast cancer (EBC): results from the GEICAM/2006–10 study
Breast Cancer Research and Treatment, Vol. 177, Núm. 1, pp. 115-125
2018
-
Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE)
Oncologist, Vol. 23, Núm. 4, pp. 422-432
-
Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy
Clinical and Translational Oncology, Vol. 20, Núm. 12, pp. 1548-1556
2017
-
A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study
Oncotarget, Vol. 8, Núm. 42, pp. 73144-73153
-
Functional proteomics outlines the complexity of breast cancer molecular subtypes
Scientific Reports, Vol. 7, Núm. 1
-
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Oncology, Vol. 18, Núm. 12, pp. 1688-1700
2016
-
Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study
Breast Cancer Research and Treatment, Vol. 156, Núm. 1, pp. 81-89
2015
-
SEOM clinical guidelines in metastatic breast cancer 2015
Clinical and Translational Oncology, Vol. 17, Núm. 12, pp. 946-955